The Ethics of Characterizing Difference: Guiding Principles on Using Racial
Categories in Human Genetics
By Sandra Soo-Jin Lee et. al.,
Genome Biology
| 07. 15. 2008
Abstract
We are a multidisciplinary group of Stanford faculty who propose ten principles to guide the use of racial and ethnic categories when characterizing group differences in research into human genetic variation.
Open letter
Since the completion of the Human Genome Project, research focused on human genetic variation, including differences among groups, has intensified. This focus has rekindled debates about the connection between genetic (DNA-level) traits and human 'racial' difference [1-5]. Scholars are divided on the question of whether racial categorization is an appropriate means of organizing potentially useful genetic data or a pernicious reification of historically destructive typologies [6,7]. To explore these issues, faculty from the humanities, social sciences, life sciences, law and medicine at Stanford University convened over the past few years to engage in an extended interdisciplinary dialog. The initial meeting consisted of a two-day workshop in 2003 that developed into an ongoing faculty research seminar sponsored by the Stanford Humanities Center, Affymetrix Corporation, the Mellon Foundation and the Research Institute of the Center for Comparative Studies on Race and Ethnicity. This seminar series, which continued for...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Lucy Tu, The Guardian | 11.05.2025
Beth Schafer lay in a hospital bed, bracing for the birth of her son. The first contractions rippled through her body before she felt remotely ready. She knew, with a mother’s pit-of-the-stomach intuition, that her baby was not ready either...